[go: up one dir, main page]

AR080709A1 - Derivados de triazina disustituidos farmaceuticamente activos - Google Patents

Derivados de triazina disustituidos farmaceuticamente activos

Info

Publication number
AR080709A1
AR080709A1 ARP110100926A ARP110100926A AR080709A1 AR 080709 A1 AR080709 A1 AR 080709A1 AR P110100926 A ARP110100926 A AR P110100926A AR P110100926 A ARP110100926 A AR P110100926A AR 080709 A1 AR080709 A1 AR 080709A1
Authority
AR
Argentina
Prior art keywords
cr62r63
cycle
nhco
cr49r50
cr86r87
Prior art date
Application number
ARP110100926A
Other languages
English (en)
Inventor
Peter Nussbaumer
Gerd Ruhter
Ulrich Lucking
Axel Choidas
Jan Eickhoff
Carsten Schultz-Fademrecht
Klebl Bert Dr
Original Assignee
Lead Discovery Center Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center Gmbh filed Critical Lead Discovery Center Gmbh
Publication of AR080709A1 publication Critical patent/AR080709A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a derivados de triazina disustituidos y/o sales farmacéuticamente aceptables de ellos, el uso de estos derivados como agentes farmacéuticamente activos, en especial para la profilaxis y/o el tratamiento de enfermedades infecciosas, incluyendo enfermedades oportunistas, enfermedades inmunologicas, enfermedades autoinmunes, enfermedades cardiovasculares, enfermedades celulares proliferativas, inflamacion, disfuncion eréctil y apoplejía, y a composiciones farmacéuticas conteniendo al menos uno de dichos derivados de triazina disustituidos y/o las sales farmacéuticamente aceptables de ellos. Además la presente se refiere al uso de dichos derivados de triazina disustituidos como inhibidores de una proteína quinasa. Reivindicacion 1: Compuestos de la formula general (1) en que R1 es como en las formulas (2), L es un enlace o -CR5R6-, -CR5R6-CR7R8-, -CR5R6-CR7R8-CR9R10-, CR5R6-CR7R8-CR9R10-CR11 R12-; R5-R12 representan independientemente uno del otro -H, -CH3, -C2H5, -C3H7, -F, -CI, -Br, I; R3 está seleccionado de -H, -NO2, -NH2, -CN, -F, -CI, -Br, -I, -CH3, -C2H5, -Ph, -C3H7, -CH(CH3)2, -C4H9, -CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3, -O-CH3, -O-C2H5, -O-C3H7, -O-CH(CH3)2, -O-C4H9, -O-CH2-CH(CH3)2, -O-CH(CH3)-C2H5, -O-C(CH3)3, -CR13R14R21, -CR13R14-CR15R16R21, -O-CR13R14R21, -CR13R14-CR15R16-CR17R18R21, -CR13R14-CR15R16-CR17R18-CR19R20R21, -O-CR13R14-CR15R16R21, -O-CR13R14-CR15R16-CR17R18R21, -SO2R22, -CONR23R24, -NR25COR22, -O-CR13R14-CR15R16-CR17R18-CR19R20R21, -NR25SO2NR23R24, -NR25SO2R22, -NR25CONR23R24, -SO2NR23R24, -SO(NR26)R27, -NH-CO-NH-Ph; R13-R21, R29-R32 y R33-R48 representan independientemente uno del otro -H, -F, -CI, -Br, -I; R26 es -H, -CH3, -C2H5, -C3H7, -CH(CH3)2, -C4H9, -CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3, -C5H11, -CH(CH3)-C3H7, -CH2-CH(CH3)-C2H5, -CH(CH3)-CH(CH3)2, -C(CH3)2-C2H5, -CH2-C(CH3)3, -CH(C2H5)2, -C2H4-CH(CH3)2, -C6H13, -C3H6-CH(CH3)2, -C2H4-CH(CH3)-C2H5, -CH(CH3)-C4H9, -CH2-CH(CH3)-C3H7, -CH(CH3)-CH2-CH(CH3)2, -CH(CH3)-CH(CH3)-C2H5, -CH2-CH(CH3)-CH(CH3)2, -CH2-C(CH3)2-C2H5, -C(CH3)2-C3H7, -C(CH3)2-CH(CH3)2, -C2H4-C(CH3)3, -CH(CH3)-C(CH3)3, -CR13R14R21, -COR28, -CR13R14-CR15R16R21, -CR13R14-CR15R16-CR17R18-CR19R20-CR29R30R21, -CR13R14-CR15R16-CR17R18R21, -CR13R14-CR15R16-CR17R18-CR19R20R21, -CR13R14-CR15R16-CR17R18-CR19R20-CR29R30-CR31R32R21, -COOR28, formulas (3) estos grupos cicloalquílicos C3-6 pueden ser sustituidos además por uno, dos, tres, cuatro, cinco o más sustituyentes seleccionados del grupo que consiste de R33-R48; R22, R27 y R28 se seleccionan independientemente de -CR49R50R51, -CR49R50-CR52R53R51, -CR49R50-CR52R53-CR54R55-CR56R57-CR58R59R51, -CR49R50-CR52R53-CR54R55R51, -CR49R50-CR52R53-CR54R55-CR56R57R51, -CR49R50-CR52R53-CR54R55-CR56R57-CR58R59-CR60R61R51, -CH2Ph, -CH2Ph cuyo grupo fenil puede ser sustituido además por uno, dos, tres, cuatro, cinco o más sustituyentes seleccionados del grupo que consiste de R5-R12 grupos cicloalquílicos C3-6 listados para R26, que pueden ser sustituidos por uno, dos, tres, cuatro, cinco o más sustituyentes seleccionados del grupo que consiste de R33-R48; R49-R61 representan independientemente uno del otro -H, -CH3, -C2H5, -C3H7, -C4H9, -F, -CI, -Br, -I, -OH, -NO2, -NH2; R23 y R24 se seleccionan independientemente de -H, -CR49R50R51, -CR49R50-CR52R53R51, -CR49R50-CR52R53-CR54R55-CR56R57-CR58R59R51, - CR49R50-CR52R53-CR54R55R51, -CR49R50-CR52R53-CR54R55-CR56R57R51, -CR49R50-CR52R53-CR54R55-CR56R57-CR58R59-CR60R61R51, -CR49R50-CR52R53-O-R51', -CR49R50-CR52R53-CR54R55-O-R51', -CR49R50-CR52R53-NR51'R51ö, -CR49R50-CR52R53-CR54R55-NR51'R51ö, -CR49R50-CR52R53-CR54R55-CR56R57-NR51'R51ö, -CR49R50-CR52R53-CR54R55-CR56R57-CR58R59-NR51'R51ô, fenil, fenil sustituido, bencil, bencil sustituido, o los dos residuos R23 y R24 juntos forman con el átomo de nitrogeno al que están ligados una acetidina, pirrolidina, piperidina, piperazina, azepana o anillo morfolino; R51' y R51ö representan independientemente uno del otro -H, -CH3, -C2H5, -C3H7, -C4H9, -CH2Ph, -COOC(CH3)3, -COOCH3, -COOCH2CH3, -COOCH2CH2CH3, -COOCH(CH3)2, -COOCH2Ph, -COCH3; y R25 es -H, -CH3, -C2H5, -C3H7, -CH(CH3)2, -C4H9, -CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3; R4 se selecciona de -H, -NO2, -NH2, -CN, -F, -CI, -Br, -I, -CR62R63R64, grupo de formulas (4), -CONH2, -SO2CH3, -SO2C2H5, -SO2C3H7, -NH-SO2-CH3, -NH-SO2-C2H5, -NH-SO2-C3H7, -NHCO-CH3, -NHCO-C2H5, -NHCO-C3H7, -SO2NR23R24, -CH2-SO2NR23R24, -C2H4-SO2NR23R24, -C3H6-SO2NR23R24, -SO2NH2, -CH2-SO2NH2, -C2H4-SO2NH2, -C3H6-SO2NH2, -O-CR62R63-CR65R66R64, -O- CR62R63-CR65R66-CR67R68R64, -CR62R63-CR65R66-CR67R68-CR69R70R64, -O-CR62R63-CR65R66-CR67R68-CR69R70R64, -CR62R63-CR65R66-CR67R68R64, -O-CR62R63-CR65R66-CR67R68-CR69R70-CR71R72R64, -CR62R63-CR65R66R64, -O-CR62R63-CR65R66-CR67R68-CR69R70-CR71R72-CR73R74R64, -O-CR62R63R64, -CR62R63-CR65R66-CR67R68-CR69R70-CR71R72R64, --CR62R63-CR65R66-CR67R68-CR69R70-CR71R72-CR73R74R64, -OCH2Ph, grupo de formulas (3) y (5) estos grupos cicloalcoxi C3-6 y grupos cicloalquílicos C3-6 pueden estar sustituidos además por uno, dos, tres, cuatro, cinco o más sustituyentes seleccionados del grupo que consiste de R33-R48, R62-R74 representan independientemente uno del otro -H, -ciclo-C3H5, -ciclo-C4H7, -ciclo-C5H9, -CR75R76R77, -CR75R76-CR78R79R77, -CR75R76-CR78R79-CR80R81R77, -CR75R76-CR78R79-CR80R79-CR82R81R77, -F, -CI, -Br, -I, -Ph; R75-R82 representan independientemente uno del otro -H, -F, -CI, -Br, -I, -NH2; R4 junto con R22, R23, R24 o R25 puede formar un grupo -CH2CH2- o -CH2CH2CH2- si R4 está ligado en orto a -L-R3; R2 es como en formulas (6), R83 se selecciona de -H, -OH, -NO2, -CN, -F, -CI, -Br, -I, -CF3, -NR23'R24', -CR62R63R64, -CR62R63-NR23'R24', -CR62R63-CR65R66R64, -CR62R63-CR65R66-NR23'R24', -CR62R63-CR65R66-CR67R68R64, -CR62R63-CR65R66-CR67R68-NR23'R24', -O-CR62R63R64, -O-CR62R63-CR65R66R64, -O-R62R63-CR65R66-CR67R68R64, -CHO, -CH2OH, -CR23'O, -CH2OR23'; R23' y R24' representan independientemente uno del otro -H, -CH3, -C2H5, -C3H7, -CH(CH3)2, -C4H9, -CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3; -(ciclo-C3H5); x es un valor entre 0 y 3; B es un enlace, -CR86R87-, -CR86R87-CR88R89-, -CR86R87-CR88R89-CR90R91-, -CR86R87-CR88R89-CR90R91-CR92R93-, -CR86R87-CR88R89-CR90R91-CR92R93-CR94R95-, -CR86R87-CR88R89-CR90R91-CR92R93-CR94R95-CR96R97-; R86-R97 representan independientemente uno del otro -H, -CH3, C2H5, -C3H7, -C4H9, -F, -CI, -Br, -I; Y es un enlace, -O-, -S-, -SO-, -SO2-, -SO2NH-, -NHSO2-, -CO-, -COO-, -OOC-, -CONH-, -NHCO-, -NH-, -N(CH3)-, -NH-CO-NH-, -O-CO-NH-, -NH-CO-O-; R84 se selecciona de un enlace, -CR86R87-, -CR86R87-CR88R89-CR90R91-, -CR86R87-CR88R89-CR90R91-CR92R93-, -CR86R87-CR88R89-CR90R91-CR92R93-CR94R95-, -CR86R87-CR88R89-, -CR86R87-CR88R89-CR90R91-CR92R93-CR94R95-CR96R97-; R85 se selecciona de (i) -H, -OH, -OCH3, -OC2H5, -OC3H7, -O-ciclo-C3H5, -OCH(CH3)2, -OC(CH3)3, -OC4H9, -Ph, -OPh, -OCH2-Ph, -OCPh3, -SH, -SCH3, -SC2H5, -SC3H7, -S-ciclo-C3H5, -SCH(CH3)2, -SC(CH3)3, -SC4H9, -NO2, -F, -CI, -Br, -I, -P(O)(OH)2, -P(O)(OCH3)2, -P(O)(OC2H5)2, -P(O)(OCH(CH3)2)2, -Si(CH3)2(C(CH3)3), -Si(C2H5)3, -Si(CH3)3, -CN, -CHO, -COCH3, -COC2H5, -COC3H7, -CO-ciclo-C3H5, -COCH(CH3)2, -COC(CH3)3, -COC4H9, -COOH, -COOCH3, -COOC2H5, -COOC3H7, -COOC4H9, -COO-ciclo-C3H5, -COOCH(CH3)2, -COOC(CH3)3, -OOC-CH3, -OOC-C2H5, -OOC-C3H7, -OOC-C4H9, -OOC-ciclo-C3H5, -OOC-CH(CH3)2, -OOC-C(CH3)3, -CONR23'R24', -NHCOCH3, -NHCOC2H5, -NHCOC3H7, -NHCO-ciclo-C3H5, -NHCO-CH(CH3)2, -NHCOC4H9, -NHCO-C(CH3)3, -NHCO-OCH3, -NHCO-OC2H5, -NHCO-OC3H7, -NHCO-O-ciclo-C3H5, -NHCO-OC4H9, -NHCO-OCH(CH3)2, -NHCO-OC(CH3)3, -NHCO-OCH2Ph, -NR23R24, -CF3, -SOCH3, -SOC2H5, -SOC3H7, -SO-ciclo-C3H5, -SOCH(CH3)2, -SOC(CH3)3, -SO2CH3, -SO2C2H5, -SO2C3H7, -SO2-ciclo-C3H5, -SO2CH(CH3)2, -SO2C4H9, -SO2C(CH3)3, -SO3H, -SO2NR23'R24', -OCF3, -OC2F5, -O-COOCH3, -O-COOC2H5, -O-COOC3H7, -O-COO-ciclo-C3H5, -O-COOC4H9, -O-COOCH(CH3)2, -O-COOCH2Ph, -O-COOC(CH3)3, -NH-CO-NH2, -NH-CO-NHCH3, -NH-CO-NHC2H5, -NH-CO-NHC3H7, -NH-CO-NHC4H9, -NH-CO-NH-ciclo-C3H5, -OCH2-ciclo-C3H5, -NH-CO-NH[CH(CH3)2], -NH-CO-NH[C(CH3)3], -NH-CO-N(CH3)2, -NH-CO-N(C2H5)2, -NH-CO-N(C3H7)2, -NH-CO-N(C4H9)2, -NH-CO-N(ciclo-C3H5)2, -NH-CO-N[CH(CH3)2]2, -NH-CO-N[C(CH3)3]2, -NH-C(=NH)-NH2, -NH-C(=NH)-NHCH3, -NH-C(=NH)-NHC2H5, -NH-C(=NH)-NHC3H7, -NH-C(=NH)-NHC4H9, -NH-C(=NH)-NH-ciclo-C3H5, -NH-C(=NH)-NH[CH(CH3)2], -NH-C(=NH)-NH[C(CH3)3], -NH-C(=NH)-N(CH3)2, -NH-C(=NH)-N(C2H5)2, -NH-C(=NH)-N(C3H7)2, -NH-C(NH)-N(ciclo-C3H5)2, -NH-C(=NH)-N(C4H9)2, -NH-C(=NH)-N[CH(CH3)2]2, -NH-C(=NH)-N[C(CH3)3]2, -O-CO-N H2, -O-CO-NHCH3, -O-CO-NHC2H5, -O-CO-NHC3H7, -O-CO-NHC4H9, -O-CO-NH-ciclo-C3H5, -O-CO-NH[CH(CH3)2], -O-CO-NH[C(CH3)3], -O-CO-N(CH3)2, -O-CO-N(C2H5)2, -O-CO-N(C3H7)2, -O-CO-N(C4H9)2, -O-CO-N(ciclo-C3H5)2, -O-CO-N[CH(CH3)2]2, -O-CO-N[C(CH3)3]2, (ii) un anillo aromático o heteroaromático mono- o bicíclico seleccionado de 2-tienil, 3-tienil, 2-furanil, 3-furanil, 2-oxazolil, 3-oxazolil, 4-oxazolil, 2-tiazolil, 3-tiazolil, 4-tiazolil, 1-pirazolil, 3-pirazolil, 4-pirazolil, 5-pirazolil, 1-imidazolil, 2-imidazolil, 4-imidazolil, 5-imidazolil, fenil, 1-naftil, 2-naftil, 2-piridil, 3-piridil, 4-piridil, 2-pirimidinil, 4-pirimidinil, 5-pirimidinil, 2-pirazinil, 3-piridazinil, 4-piridazinil, 1,3,5-triazin-2-iI, compuestos de formulas (7) que opcionalmente puede estar sustituido por uno o dos sustituyentes seleccionados de -F, -CI, -Br, -I, -OCH3, -CH3, -NO2, -CN, -CF3; (iii) un anillo saturado seleccionado de ciclopentil, acetidin-1-il, compuestos de formulas (8); R99 representa -H, -CH3, -CH2Ph, -COOC(CH3)3, -COOCH3, -COOCH2CH3, -COOCH2CH2CH3, -COOCH(CH3)2, -COOCH2Ph, -COCH3; el grupo -B-Y-R-R85 junto con un sustituyente R83 puede formar un grupo -OCH2O- si R83 está ligado en posicion orto a -B-Y-R-R85; a condicion de que R83 no sea -H si el grupo -B-Y-R84-R85 es hidrogeno; R98 se selecciona de -NO2, -CN, -F, -CI, -Br, -I, -NH2, -OH, -CR62R63R64, -CR62R63-CR65R66R64, -CR62R63-R65R66-C67R68R64, -CR62R63-CR65R66-CR67R68-CR69R70R64, -O-CR62R63R64, -O-CR62R63-CR65R66R64, -O-CR62R63-CR65R66-CR67R
ARP110100926A 2010-03-22 2011-03-22 Derivados de triazina disustituidos farmaceuticamente activos AR080709A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10075131 2010-03-22

Publications (1)

Publication Number Publication Date
AR080709A1 true AR080709A1 (es) 2012-05-02

Family

ID=42224568

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100926A AR080709A1 (es) 2010-03-22 2011-03-22 Derivados de triazina disustituidos farmaceuticamente activos

Country Status (18)

Country Link
US (1) US20130079345A1 (es)
EP (1) EP2550257B1 (es)
JP (1) JP5921525B2 (es)
KR (1) KR101752519B1 (es)
CN (1) CN102933561B (es)
AR (1) AR080709A1 (es)
AU (1) AU2011231975B2 (es)
BR (1) BR112012024017B1 (es)
CA (1) CA2789200C (es)
EA (1) EA026917B1 (es)
ES (1) ES2619585T3 (es)
IL (1) IL221229A (es)
MX (1) MX2012010966A (es)
SA (1) SA111320281B1 (es)
TW (1) TWI515183B (es)
UY (1) UY33286A (es)
WO (1) WO2011116951A1 (es)
ZA (1) ZA201206262B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
EP2699554B1 (en) * 2011-04-19 2016-11-02 Bayer Intellectual Property GmbH Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2561867A1 (en) * 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9 inhibitors in the treatment of midline carcinoma
EP2562265A1 (en) * 2011-08-22 2013-02-27 Lead Discovery Center GmbH Susceptibility to selective CDK9 inhibitors
WO2013037896A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
US20150259300A1 (en) * 2012-10-18 2015-09-17 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
CA2888383A1 (en) * 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
EP2909176B1 (en) 2012-10-18 2016-07-20 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
CA2891358C (en) 2012-11-15 2021-05-18 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
CA2917096C (en) 2013-07-04 2021-05-18 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
US9063420B2 (en) 2013-07-16 2015-06-23 Rohm And Haas Electronic Materials Llc Photoresist composition, coated substrate, and method of forming electronic device
US8962779B2 (en) 2013-07-16 2015-02-24 Dow Global Technologies Llc Method of forming polyaryl polymers
US9410016B2 (en) 2013-07-16 2016-08-09 Dow Global Technologies Llc Aromatic polyacetals and articles comprising them
US8933239B1 (en) 2013-07-16 2015-01-13 Dow Global Technologies Llc Bis(aryl)acetal compounds
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
CA2942119A1 (en) 2014-03-13 2015-09-17 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
CA2944251C (en) 2014-04-01 2022-10-18 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
WO2015153870A1 (en) * 2014-04-04 2015-10-08 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
JP6605493B2 (ja) 2014-04-11 2019-11-13 バイエル ファーマ アクチエンゲゼルシャフト 新規大環状化合物
ES2720525T3 (es) 2014-10-16 2019-07-22 Bayer Pharma AG Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfona
CN107001341B (zh) 2014-10-16 2020-08-07 拜耳医药股份有限公司 含有磺亚胺基的氟化苯并呋喃基-嘧啶衍生物
US10717749B2 (en) 2015-09-29 2020-07-21 Bayer Pharma Aktiengesellschaft Macrocyclic sulfondiimine compounds
CA3001085A1 (en) 2015-10-08 2017-04-13 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
KR20180123047A (ko) 2016-03-24 2018-11-14 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CA3057892A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
EA202091894A1 (ru) 2018-02-13 2020-12-28 Байер Акциенгезельшафт Применение 5-фтор-4-(4-фтор-2-метоксифенил)-n-{4-[(s-метилсульфонимидоил)метил]пиридин-2-ил}пиридин-2-амина для лечения диффузной в-крупноклеточной лимфомы
EP3613738A1 (en) * 2018-08-23 2020-02-26 Lead Discovery Center GmbH 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer
CN109776513A (zh) * 2019-03-18 2019-05-21 福建省医学科学研究院 一类4-苯基-1,3,5-三嗪-2-胺类抗肿瘤化合物及其制备方法
KR102333854B1 (ko) 2019-10-24 2021-12-06 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN114787142B (zh) 2019-12-09 2024-08-02 石药集团中奇制药技术（石家庄）有限公司 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
CA3172328A1 (en) * 2020-03-27 2021-09-30 Haruhisa Inoue Nerve cell degeneration inhibitor
WO2022157686A1 (en) * 2021-01-22 2022-07-28 Ildong Pharmaceutical Co., Ltd. Inhibitors of anoctamin 6 protein and uses thereof
US12109210B2 (en) 2021-09-29 2024-10-08 Gongwin Biopharm Co., Ltd Methods for treating mast cell tumors
CN115089591B (zh) * 2022-05-21 2024-04-12 复旦大学 布立尼布在制备抑制肠道病毒71型嗜神经性病毒药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000229949A (ja) * 1999-02-10 2000-08-22 Nippon Soda Co Ltd 含窒素ヘテロ環誘導体
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
US7291616B2 (en) * 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
CN100412066C (zh) * 2003-09-30 2008-08-20 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
EP1878726A1 (en) 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
MX2009006536A (es) * 2006-12-22 2009-06-26 Novartis Ag Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
ES2539518T3 (es) * 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
JP5379787B2 (ja) * 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
US8507498B2 (en) 2007-04-24 2013-08-13 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
EP2231625A4 (en) 2007-12-13 2010-12-29 Glaxosmithkline Llc KINASE INHIBITORS BASED ON THIAZOLE AND OXAZOLE
EP2699554B1 (en) * 2011-04-19 2016-11-02 Bayer Intellectual Property GmbH Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines

Also Published As

Publication number Publication date
BR112012024017A2 (pt) 2016-08-30
CA2789200C (en) 2020-05-26
BR112012024017B1 (pt) 2021-12-07
AU2011231975A1 (en) 2012-08-30
TWI515183B (zh) 2016-01-01
TW201136901A (en) 2011-11-01
ES2619585T3 (es) 2017-06-26
EP2550257B1 (en) 2016-12-21
UY33286A (es) 2011-10-31
WO2011116951A1 (en) 2011-09-29
AU2011231975B2 (en) 2014-07-03
JP2013522331A (ja) 2013-06-13
IL221229A0 (en) 2012-10-31
SA111320281B1 (ar) 2015-06-04
KR101752519B1 (ko) 2017-06-29
JP5921525B2 (ja) 2016-05-24
IL221229A (en) 2017-05-29
MX2012010966A (es) 2013-01-29
CN102933561B (zh) 2016-05-11
CA2789200A1 (en) 2011-09-29
US20130079345A1 (en) 2013-03-28
EA201201309A1 (ru) 2013-04-30
KR20130006632A (ko) 2013-01-17
HK1181771A1 (zh) 2013-11-15
EA026917B1 (ru) 2017-05-31
EP2550257A1 (en) 2013-01-30
CN102933561A (zh) 2013-02-13
ZA201206262B (en) 2013-04-24

Similar Documents

Publication Publication Date Title
AR080709A1 (es) Derivados de triazina disustituidos farmaceuticamente activos
ES2567066T3 (es) Derivados de piridina disustituida farmacéuticamente activos
ES2552733T3 (es) Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
RU2386622C2 (ru) Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы
RU2011100786A (ru) Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ
AR052559A1 (es) Derivados de pirazol para inhibir cdk's y gsk's
ES2530492T3 (es) Compuestos farmacéuticamente activos como inhibidores AXL
AR057703A1 (es) INHIBIDORES MACROCíCLICOS DEL VIRUS DE LA HEPATITIS C. PROCESO DE PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS.
NO20084832L (no) Pyrimidinderivater som P13K-inhibitorer
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
SI2310396T1 (en) Macrocyclic derivatives of indole are useful as inhibitors of hepatitis C virus
AR041303A1 (es) Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4"
RU2012136643A (ru) [5,6]- гетероциклическое соединение
BRPI0511808A (pt) composto ou um sal, pró-droga ou solvato do mesmo, uso de um composto método para tratar doenças mediadas com glk, e, processo para a preparação de um composto
AR059249A1 (es) Compuesto amina trisustituido
AR070460A1 (es) Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
PE20071009A1 (es) Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3
AR112804A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos
JP2020533347A5 (es)
RU2015102024A (ru) Совместимая с глиной добавка для химических веществ, применяемых в строительной промышленности
SG179207A1 (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
RU2016108762A (ru) Бициклические ингибиторы
AR087841A1 (es) Derivados de tetrahidrotriazolopirimidina
CO5650165A2 (es) Procedimientos para la preparacion de derivados de benzoimidazol

Legal Events

Date Code Title Description
FC Refusal